Yang, Y
,
Bailey, C
Holz, F G
Eter, N
Weber, M
Baker, C
Kiss, S
Menchini, U
Ruiz Moreno, J M
Dugel, P
Lotery, A http://orcid.org/0000-0001-5541-4305
Article History
First Online: 11 March 2016
Competing interests
: YY: honoraria, advisory board—Alimera Sciences, Allergan, Alcon, Bayer, Novartis, Thrombogenics; consultancy—Alimera Sciences, Allergan. CB: honoraria—Novartis; commercial funding for clinical trial recruitment via Bristol Eye Hospital—Alimera Sciences; research funding for clinical trials work via Bristol Eye Hospital—Bayer. FH: research funding, consultancy, grants, honoraria—Alimera Sciences, Allergan, Novartis. NE: research funding, speakers bureau, honoraria, advisory board—Novartis, Bayer, Allergan; speakers bureau, honoraria—Heidelberg Engineering; advisory board—Bausch and Lomb; research funding, advisory board—Alimera Sciences. MW: honoraria, advisory board—Alimera Sciences. SK: consultancy, honoraria—Alimera Sciences, Allergan, Genentech/Roche, Regeneron, speakers bureau—Allergan, Genentech/Roche, Regeneron. PD: consultancy, honoraria—Alimera Sciences, Allergan, Alcon. AL: research funding, honoraria, advisory committee—Alimera Sciences. JMRM, UM: nothing to disclose.